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1. Introduction  
The eye is in specific environment to resist pharmaceutical approaches. Vitreoretinal 
diseases, including age-related macular degeneration (AMD) (Green & Enger, 1993; Sarks, 
1976; van der Schaft et al., 1992), are refractory to both topical and systemic pharmacological 
approaches because of specific environment of the eye. More recently, a variety of 
pharmacological challenges to treat exudative age-related macular degeneration and 
macular edema are proceeding into clinical trials, as soon as antivascular endothelial growth 
factor (anti-VEGF) therapies have been proved to be effective by repeated intravitreal 
injections. Monthly injections of anti-VEGF therapies to maximize visual potential are a 
significant treatment burden on the patient. As a result, the need for better treatments for 
AMD remains (Brown et al., 2006; Geroski & Edelhauser, 2000; Hughes, 2005; Rosenfeld et 
al., 2006) (Figure 1).  
 
Fig. 1. Different methods of drug delivery 
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Opthalmic drug delivery is one of the most interesting and challenging endeavors facing the 
pharmaceutical scientist. A significant challenge to the formulator is to circumvent the 
protective barriers of the eye without causing permanent tissue damage. Development of 
newer, more sensitive diagnostic techniques and novel therapeutic agents continue to 
provide ocular delivery systems with high therapeutic efficacy. The goal of 
pharmacotherapeutics is to treat a disease in a consistent and predictable fashion. The 
efficacy of a compound is governed by its intrinsic effects on the target site (and any other 
sites with which it comes into contact), its distribution throughout and its elimination from 
the body. Alterations to the and elimination of a compound can thus radically alter its 
efficacy. For regions of the body with a significant barrier to drug permeation, such as the 
eye and brain, great care should be taken to deliver drugs appropriately (Figure 2). 
 
Fig. 2. Diagram of the brain and spinal cord. Diagram of the brain and spinal cord 
illustrating how the eye’s inner and outer blood-retinal barriers (BRBs) fit into the overall 
scheme of blood-neural barriers (BNBs) Barriers between the blood and neural tissues are 
collectively referred to as BNBs and include the blood-brain barrier (A), the blood-CSF 
barrier (B), the BRB (C), and the blood-spinal cord barrier (D). Considering that several 
retinal disorders are accompanied by dysfunction or breakdown of this BRB and their 
associated cell-cell signaling mechanisms, elucidating the nature of the BRB is important for 
under standing normal health and disease (Choi & Kim, 2008).  
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In the design of a drug delivery system for the eye a balance must be struck between the 
limitations imposed by the physicochemical properties of the drugs, the limitations imposed 
by the anatomy and disease state of the eye, and the dosing requirements of the drug for 
that particular disease. In the recent past years review articles have focused on drug 
delivery to the eye (Acharya & Young 2004; Andreoli & Miller, 2007; Barar, Javadzadeh & 
Omidi, 2008; Barocas & Balachandran 2008; Bekeredjian, Katus & Kuecherer, 2006; Booth et 
al. 2007; Del Amo & Urtti, 2008; Gaudana et al. 2009; Hoffman, 2008; Hsu, 2007; Lee & 
Robinson, 2009; Lemley & Han, 2007; Liu & Regillo, 2004; Mitra, 2009; Novack, 2009; Sultana 
et al., 2006). The aim of this chapter is to emphasize recent advances in ocular drug delivery 
techniques most suitable for AMD. 
2. Ocular delivery systems  
2.1 Ocular barriers  
The eye is in specific environment to resist pharmaceutical approaches (Maurice & Mishima, 
1984). Systemically administered drug cannot easily reach the retina and vitreous cavity due 
to the blood-aqueous barrier, composed of ciliary non-pigmented epithelium and iridal 
vascular endothelium with tight junction (TJ) and the outer and inner BRB, which are 
formed by the retinal pigment epithelium (RPE) and retinal vascular endothelium, 
respectively. On the other hand, an eyeball is covered with collagenous walls (e.g. cornea 
and sclera) and epithelial and endothelial barriers (e.g. cornea and RPE). These barriers, 
continuous tear drainage, frontward flow of aqueous humor, and surrounding blood 
circulations limit the penetration of administered drug (e.g. eye drops and ointments) 
(Figure 3) 
 
Fig. 3. Possible barriers interfering drug delivery into the eye (Tsutomu, Yasuhiko & Hideya 
et al. 2011) 
Compliance is also problematic, particularly among patients who have chronic diseases 
such as glaucoma and refractory chorioretinal diseases, including uveitis, macular edema, 
neovascular (wet) and atrophic (dry) AMD, and retinitis pigmentosa. In this section, the 
function of ocular barrier systems is briefly described (Table 1). 
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Drug 
Delivery 
Mode 
Intravitreal 
Injection 
Sub-Tenon’s 
Injection 
Suprachoroidal/Intrascleral
Hollow Microneedle 
Injection 
Topical Drops 
Systemic Oral 
Pills 
Pathway to 
target 
posterior 
segment   
Direct Transscleral Transchoroidal  
Transconjunctival/ 
transscleral  
Trans-RPE 
Safety      
Risk 
Highest 
injection risk 
Highest 
injection risk, 
mild systemic 
exposure 
Minimal injection risk, 
minimal systemic exposure
Safest, but moderate 
systemic exposure 
Minimal local 
exposure; 
highest 
systemic 
exposure 
Adverse 
Events 
Vitreous 
hemorrhage, 
retinal 
detachment, 
endophthalmitis
Subconjunctival 
hemorrhage 
Subconjunctival 
hemorrhage, 
suprachoroidal  
hemorrhage 
Conjunctival redness 
and irritation 
Gastrointestinal 
upset 
Efficacy 
Most direct and 
effective  
(only mode  
that directly 
penetrates BRB)
Much less 
bioavailable to 
the vitreous 
and retina 
80-fold more bioavailable 
than 
sub-Tenon’s injection 
Worst bioavailability 
and second worst 
duration of action; 
convenient and  
can be self-
administered  
at home 
Second worst 
bioavailability 
and worst 
duration of 
action 
Peak 
bioavailability 
     
Intravitreal 100% 0.01%–0.1% 0.8%–70% 0%–0.0004% 0%–2% 
Intra-aqueous 
humor 
3% 0.008%–0.8% 0.02%–2.1% 0.0007%–5% 1%–2% 
Duration of 
action 
21 Hours to 7 
weeks 
6 Hours to 1 
month 
18 Hours to 3 months 30 Minutes to 4 hours <30 Minutes 
Table 1. Drug delivery routes for Age-related macular de generation 
2.2 Tear, cornea, conjunctiva and sclera 
Tear: One of the precorneal barriers is tear film which reduces the effective concentration of 
the administrated drugs due to dilution by the tear turnover (approximately 1 µL/min), 
accelerated clearance, and binding of the drug molecule to the tear proteins (Craig, 2002).  
Cornea: The cornea consists of three layers; epithelium, stroma and endothelium, with each 
one possessing a different polarity, rate-limiting structure for drug penetration and a 
mechanical barrier to inhibit transport of exogenous substances into the eye (Pederson, 
2006). The corneal epithelium is characterized by tight junctions among cells; these are 
formed to restrict paracellular drug permeation from the tear film. The highly hydrated 
structure of the stroma (extracellular matrix of a lamellar arrangement of collagen fibrils) 
acts as a barrier to permeation of lipophilic drug molecules. Corneal endothelium acts as a 
separating barrier between the stroma and aqueous humor (Fischbarg, 2006). . 
Conjunctiva: Conjunctiva or episclera has a rich supply of capillaries and lymphatics 
therefore, administrated drugs in the conjunctival or episcleral space may be cleared 
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through blood and lymph (Gausas, Gonnering, Lemke, et al. 1999; Singh, 2003; Sugar, Riazi, 
& Schaffner, 1957). The conjunctival blood vessels do not form a TJ barrier which means 
drug molecules can enter into the blood circulation by pinocytosis and/or convective 
transport through paracellular pores in the vascular endothelial layer. The conjunctival 
lymphatics act as an efflux system for the efficient elimination from the conjunctival space. 
Drugs transported by lymphatics in conjunction with the elimination by blood circulation 
can contribute to systemic exposure, since the interstitial fluid is returned to the systemic 
circulation after filtration through lymph nodes (Lee, He, Robinson, et al. 2010).  
Slera: Scleral permeability has been shown to have a strong dependence on the molecular 
radius (it consists of collagen fibers and proteoglycans embedded in an extracellular matrix); 
scleral permeability decreases roughly exponentially with molecular radius (Oyster, 1999). 
The ideal location for transscleral drug delivery is near the equator at 12–17 mm posterior to 
the corneoscleral limbus. Hydrophobicity of drugs affects scleral permeability; increase of 
lipophilicity shows lower permeability; and hydrophilic drugs may diffuse through the 
aqueous medium of proteoglycans in the fiber matrix pores more easily than lipophilic 
drugs. 
2.3 Choroid/Bruch’s membrane and retina 
Choroid/Bruch’s Membrane: Choroid is one of the most highly vascularized tissues of the 
body. The choroidal capillary endothelial cells are fenestrated and, are relatively large in 
diameter (20–40 µm). Previous histological studies have shown choroidal thickness changes 
from 200 µm at birth decreasing to about 80 µm by age 90 (Spaide, 2009). In contrast, Bruch’s 
membrane (BM) causes thickening with age (Tout, Chan-Ling, Hollander, et al. 1993). These 
changes cause increased calcification of elastic fibers, increased cross-linkage of collagen 
fibers and increased turnover of glycosaminoglycans. Thickness changes of choroid and BM 
might affect drug permeability from subconjunctiva or episcleral space into the retina and 
the vitreous (Farboud, Aotaki-Keen, Miyata, et al. 1999; Handa, Verzijl, Matsunaga, et al. 
1999; Hewitt, Nakazawa & Newsome, 1989; Hewitt & Newsome, 1985; Spraul, Lang, 
Grossniklaus, H.E. et al. 1999; Tout, Chan-Ling, Hollander, et al. 1993; Yamada, Ishibashi, 
Bhutto, et al. 2006). 
Retina: in the vitreous drugs are eliminated by two main routes from anterior and posterior 
segments. Elimination via the posterior route takes place by permeation across the retina. In 
intact retina, the drugs in the subretinal fluid could either be absorbed by the sensory retinal 
blood vessels or transported across the RPE, where it may be absorbed into the choroidal 
vessels or pass through the sclera. Drug transport across the RPE takes place both by 
transcellular and paracellular routes. The driving forces of outward transport of molecules 
from the subretinal spaces are hydrostatic and osmotic, and small molecules might transport 
through the paracellular inter-RPE cellular clefts and by active transport through the 
transcellular route (Pederson, 2006). 
2.4 Blood retinal barrier 
The BRB controls the flux of fluid and blood-borne elements into the neural parenchyma, 
helping to establish the unique neural environment necessary for proper neural function.  
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BRB restricts drug transport from blood into the retina. BRB is composed of tight junctions 
(TJ) of retinal capillary endothelial cells and RPE, called iBRB for the inner and oBRB for the 
outer BRB, respectively. The function of iBRB is supported by Müller cells and astrocytes 
(Cunha-Vaz, 1979). 
Müller cells are known to support neuronal activity and maintain the proper functioning of 
the iBRB under normal conditions.The astrocytes are closely associated with the retinal 
capillary vessels and help to maintain the capillary integrity (Zhang & Stone, 1997). 
Astrocytes are known to increase the barrier properties of the retinal vascular endothelium 
by enhancing the expression of the tight junction protein ZO-1 and modifying endothelial 
morphology (Gardner, Lieth, Khin, et al. 1997).  
Following systemic drug administration, drugs can easily enter into the choroid since 
choroid is highly vascularized tissue compared to retina. The choriocapillaris are fenestrated 
resulting in rapid equilibration of drug molecules present in the bloodstream with the 
extravascular space of the choroid. Therefore, oBRB (RPE) restricts further entry of drugs 
from the choroid into the retina. RPE is a monolayer of highly specialized hexagonal-shaped 
cells, located between the sensory retina and the choroid. The TJ of the RPE efficiently 
restrict intercellular permeation into the sensory retina. Dysfunction of Müller cells may 
contribute to a breakdown of the iBRB in many pathological conditions (Tretiach, Madigan, 
Wen, et al. 2005). Müller cells enhance the secretion of VEGF under hypoxic and 
inflammatory conditions (Eichler, Kuhrt, Hoffmann, et al. 2000; Kaur, Sivakumar & Foulds, 
2006). VEGF-induced occluding phosphorylation and ubiquitination causes trafficking of 
tight junction and leads to increased retinal vascular permeability (Murakami, Felinski & 
Antonetti, 2009).  
3. Drug delivery systems to posterior segment of the eye and specific 
delivery systems  
In drug delivery, a more common situation is one where the rate of change of concentration 
is directly proportional to the concentration of drug present, and drug’s potential to diffuse 
from one region to another is directly proportional to its chemical potential, which can 
usually be approximated to its concentration. This situation is termed first order and can be 
expressed as (Higuchi, 1961) 
 - dc/dt = kc  
where dc is the change in concentration, dt is the time interval over which that change 
occurs, k is a constant, also known as the rate constant, and it is in function of concentration.  
Integrating this with respect to time gives (Peppas, 1995) 
 ln Ct – ln C0 = - kt  
where C0 is the initial concentration and Ct is the concentration at time t. 
A more common situation arises when drug release is both a function of its concentration 
within a vehicle and its ability to diffusion through it. When placed into a release medium, 
the drug closest to the surface is released the fastest. Over a period of time, the drug must 
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diffuse from further and further back within the bulk of the device, which progressively 
slows the release. 
Systems such as this can be described by solutions to Ficks’s second law of diffusion 
(Knight, 1981) 
 ∂C/∂t = D∂2C/dx2   
where C is the concentration in a reservoir, t the time, x the distance and D the diffusion 
coefficient the diffusant through the media. Partial derivatives (∂) are used because C is a 
function of both t and x. 
These formulae can be readily applied to drug release from ointments and gels typically 
used in eye drops, but an objective difficulty exist in finding a flawless technique to deliver 
drugs targeting diseases that directly affect the retina and vitreous humor, owing to the 
anatomic barriers and physiologic clearance mechanisms of the BRB. In this scenario a 
relevant implication have the importance of the transcellular and paracellular transport 
pathways across or between epithelial or endothelial BRBs. TJs are the most apical 
component of both the epithelial or endothelial intercellular junctional complexes. TJs are 
crucial for the formation and maintenance of epithelial and endothelial paracellular barriers 
since they semipermeably regulate intercellular passive diffusion of large or hydrophilic 
ions and solutes. Moreover, a complex network of TJ proteins have been identified, with the 
assembly and dynamic maintenance of various claudin proteins being the most crucial in 
regard to dictating the selectivity of this paracellular barrier. Using the transcellular route, 
drugs are delivered by simple passive diffusion to bind with cell surface membrane–bound 
transporters (cell surface receptors, pumps, channels, and transporters) where they can 
directly cross the cell via passive diffusion again or through active transport mechanisms. 
Various influx and efflux transporters have been found for small lipophilic peptides, organic 
anions, and cations. Transporter-mediated drug delivery is tissue-specific and has low 
toxicity since transmembrane concentration gradients are not required for it works. The 
transcellular pathway is not suitable for high-throughput production of drug candidates 
though, unlike the paracellular pathway, which is suitable for highthroughput production 
since drug modification is not needed and one method can be applied for various drugs. 
Knowing the rate-limiting tissue barrier based on the physiochemical properties of a drug 
helps when optimizing the absorption of passively penetrated drugs. 
3.1 Intravitreal injections and intraocular drug delivery 
Intraocular drug delivery is the only mode that currently directly broaches the BRB and 
thereby attains the highest peak intravitreal or intraretinal drug concentrations. However, 
intraocular drug delivery is the most invasive than other approaches, in that it involves 
penetrating the globe and thus is not free of injection-related complications. These 
complications may include trauma and increased risk of cataract, retinal detachment, 
hemorrhage and endophthalmitis (Jager, Aiello, Patel, et al. 2004). 
Moreover, the presence of some moderate clearance mechanisms (posterior transretinal and 
anterior aqueous humor elimination pathways) cause the peak drug concentration levels 
achieved with intraocular administration to decline to non-therapeutic trough levels over 
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time, unless the injections are given frequently and repeatedly. The disadvantage caused by 
the short to medium duration of action of intravitreal drug solutions has been partially 
alleviated through product formulation or drug device development. Currently, despite its 
shortcomings, intravitreal administration is the preferred drug delivery route to treat 
diseases of the posterior segment being the better approach achieving the highest 
intraocular bioavailability in posterior segment tissues such as the cone-containing macula 
or fovea.  
Anti-VEGF drugs, such as pegaptanib, ranibizumab and bevacizumab are new intravitreal 
treatments for AMD. To understand the pharmacokinetics of intravitreal drug delivery a 
great attention should be made to understanding the molecular structure of the normal 
human vitreous gel and that normal vitreous gel undergoes age-related degenerative 
liquefaction. It was shown that immediately after intravitreal injection, drugs initially 
concentrate near the injection site or in the cisternae forming vitreous concentration 
gradients before distributing throughout the entire vitreous cavity and then reaching steady 
state equilibrium levels (Lee SS, et al. IOVS 2009;50:ARVO E-Abstract 5950). The location of 
implant placement in the vitreous (anterior placement behind lens versus posterior 
placement near the retina) influences drug levels in various tissues. When the implant was 
placed in the posterior region, drug levels were higher in the posterior retina, choroid-RPE 
and sclera and lower in the anterior retina, choroid-RPE, and sclera. Posterior placement of 
the implant is likely to support release of the drug to target tissues in case of retinal 
disorders. Although the posterior implant reduced drug levels in the lens, no such 
advantage was found with respect to corticosteroid levels in the trabecular meshwork, 
possibly due to the high affinity of the drug for this tissue.  
After intravitreal placement of an implant, drug levels are not likely to achieve a uniform 
level throughout the vitreous. However, it is probable that a slow release system achieves 
zones of steady state concentration, with the contours dictated by the clearance mechanisms 
of a given therapeutic agent. The reason for such zones or contours of steady state 
concentration is not necessarily diffusion limitation, but rather the presence of continuous 
dynamic clearance mechanisms in the posterior segment. There are two main mechanisms 
of drug clearance for intravitreally administered drugs in the eye: the anterior elimination 
pathway via counterdirectional bulk aqueous flow and the posterior elimination pathway 
via vitreoretinochoroidal bulk flow due to hydrostatic and osmotic pressure gradients in the 
inner, middle, and outer coats of the posterior segment (Kim, Lutz, Wang, et al. 2007). An 
additional mechanism to consider is the transcellular carrier–mediated transporters found 
on the RPE. Influx transporters enhance the penetration of drugs and efflux transporters 
inhibit retention of drugs across the outer (o)BRB (Mannermaa, Vellonen & Urtti, 2006). The 
duration of action of an intravitreally administered drug may in part depend on the 
retention of the injected drug at the site of administration. The longer the intravitreal half-
life, the greater the anticipated duration of therapeutic response. The half-lives of drugs that 
are eliminated through both the retina and the aqueous humor, such as small lipophilic 
drugs, tend to be shorter than the half-lives of drugs eliminated primarily via the anterior 
route, such as large hydrophilic drugs, and also intravitreal drug elimination depends on 
the molecular weight (MW) of the drug, with larger MW (> 70,000) drugs displaying longer 
half-lives. To overcoming the short to medium duration of action of intravitreal drug 
solutions is the use of one of several available sustained drug release systems. These systems 
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may act through formulation modification to decrease the solubility of the drug via a 
suspension or to enhance the residence time in vitreous humor via a biodegradable implant, 
or through the use of a sustained release delivery device. 
3.2 Non-biodegradable, biodegradable implants in AMD 
Non-biodegradable implants are a reservoir type, which possesses a coating of non-
biodegradable polymers such as poly (vinyl alcohol) (PVA), ethylene vinyl acetate (EVA), 
and silicone laminate, reserving drug in the inner space. This type exhibits the most stable 
and long-standing release profile of drug, as compared with other types of implants, 
because it can reserve a large amount of drug and regulate drug release just by surface area 
and thickness of PVA, a permeable polymer (Okabe, Kimura, Okabe, et al. 2003; Yasukawa, 
Ogura, Kimura, et al. 2006; Yasukawa, Ogura, Tabata, et al. 2004). However should be 
considered the weakness of this type of device involving relatively large size of the device 
requiring a large incision for implantation, which may increase the risk of retinal 
complications (vitreous hemorrhage, epiretinal membrane, and retinal detachment), and 
potential need of removal surgery to exchange the implant or treat possible complications 
such as retinal detachment and drug-induced adverse effects (Callanan, 2007). As compared 
with non-biodegradable implants, biodegradable implants have following merits: no need 
of removal surgery and the flexibility in shape. They can be processed into a variety of 
configurations involving microparticles, a rod, a disc, or tablet. Thus, the release profile of 
drug from this 2nd generation biodegradable implants may become as stable as non-
biodegradable ones, while the duration of drug release may be shorter due to the limitation 
of drug contained. The drugs in the biodegradable implants are conjugated to a variety of 
polymers including poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic 
acid) (PLGA), poly(caprolactone) and poly(methylene malonate) (table 2). 
 
Active ingredient Brand name Dosage form 
Release-controlling 
excipient 
target indication 
fluocinolone 
acetonide 
illuvien ® IVT, implant Polyimide/PVA wet AMD, DME 
Brimonidina - IVT, implant PLGA Dry AMD, RP 
CNTF 
(NT-501) 
- IVT, implant 
semipermeabile 
membrane/ARPE-19 
RP, dry AMD 
Table 2. Current and future drugs in clinical trials for posterior disease (AMD) 
The ongoing clinical trial clearly indicates that biodegradable polymers are biocompatible. 
In the near future, many types of biodegradable implants and microparticles will proceed 
for clinical trial. 
An injectable, rod-shaped intravitreal implant with FA (Iluvien®, Alimera Sciences, 
Alpharetta, GA, U.S.) (length: 3.5 mm, diameter: 0.37 mm) has been developed for the 
treatment of diabetic macular edema (DME). Iluvien® is made of polyimide and PVA,  
small enough to be injected using an inserter with a 25-gauge needle and is expected to 
provide sustained delivery of FA to the back of the eye for up to three years. In addition to 
DME, Iluvien® is in Phase II for the treatment of wet AMD compared to Lucentis® 
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(ClinicalTrials.gov The MAP Study: Fluocinolone acetonide (FA)/MedidurTM  
for age related macular degeneration (AMD) Pilot. (2010). Available online: 
http://clinicaltrials.gov/ct2/show/ NCT00605423?term=Iluvien&rank=12), dry AMD 
(ClinicalTrials.gov Fluocinolone acetonide intravitreal inserts in geographic atrophy. (2010). 
Available online: http://clinicaltrials.gov/ct2/show/NCT00695318?term=Iluvien&rank=15.   
Brimonidine is an a2 adrenergic agonist, which can release various neurotrophins including 
brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) 
(Lonngren, Napankangas, Lafuente, et al. 2006; Kim, Chang, Kim, et al. 2007).  
These neurotrophins have a potential to prevent apoptosis of photoreceptors and/or RPE 
(Azadi, Johnson, Paquet-Durand, et al. 2007; Zhang, Mo, Fang, et al. 2009). PLGA 
intravitreal implant with two doses (200 mg, 400 mg) of brimonidine tartrate similar  
to Ozurdex® is now in Phase II clinical study for dry AMD (ClinicalTrials.gov Safety  
and efficacy of brimonidine intravitreal implant in patients with geographic atrophy  
due to age-related macular degeneration (AMD). (2010). Available online: 
http://clinicaltrials.gov/ct2/show/NCT00658619), and phase I/II clinical trials for RP 
(ClinicalTrials.gov An exploratory study to evaluate the safety of brimonidine intravitreal 
implant in patients with retinitis pigmentosa. (2010). Available online: 
http://clinicaltrials.gov/ct2/show/ NCT00661479) by Allergan, Inc. Neurotech 
Pharmaceuticals, Inc. (Lincoln, RI, U.S.) has been developing ―”Encapsulated Cell 
Technology”, this is an implantable intravitreal device that uses genetically modified ARPE-
19 RPE cells (transfected with plasmid gene insertion techniques) to release a therapeutic 
growth factor protein, ciliary neurotrophic factor (CNTF), with zero-order kinetics. CNTF is 
a neurotrophic growth factor with profound antiapoptotic effects that prolong the lives of 
dying photoreceptor cells. The cells are encapsulated within a semipermeable, hollow-fiber 
membrane, intravitreal implant device so that the CNTF protein is released to ocular tissues 
but the modified RPE cells are immunologically isolated from the patient, avoiding immune 
rejection. Phase 2 trials showed that this delivery system was safe, and a dose-dependent 
biological effect on the retina was observed. Potential visual benefit was also  
shown in patients with geographic atrophy (US National Institutes of Health. 
ClinicalTrials.org. NCT00447954 CgI. A Study of an Encapsulated Cell Technology (ECT) 
Implant for Patients With Atrophic Macular Degeneration. Phase II study. (2009). 
http://clinicaltrials.gov/ct2/show/NCT00447954). The duration of action of this 
encapsulated cell therapy device was found to be up to 2 years. Next-phase clinical trials are 
under way to continue to evaluate encapsulated cell technology (ECT)-CNTF’s effectiveness 
for the treatment of dry AMD and retinitis pigmentosa. 
Anti-VEGF compounds are now required to be administered into the eye every 4 to 6 weeks. 
Moreover, vitrectomized eyes highly increase the clearance rate of injected drugs and are, 
therefore, refractory to these drugs. The companies are currently interested in new methods 
of prolongation of residence time of intravitreally-injected drugs such as ranibizumab and 
pegaptanib. Viscous medium such as hyaluronic acid or gelling solution are considered as 
an additive to prolong drug residence in the vitreous cavity (Table 3) (Lyons, Ma & Trogde, 
2009; Giese, Kaufmann & Klippel-Giese, 2004; McSwiggen, Beigelman, Macejak, et al. 2003; 
Robinson, Blanda, Hughes, et al. 2010; Robinson, Blanda, Liu, et al. 2010; Robinson, Tsai, 
Almazan, et al. 2010). 
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Patent No. Activity 
WO2003070918 Technology of siRNA modification to improve biological stability 
WO2004015107 Technology of siRNA modification to improve biological stability 
US20100015158 
Intraocular delivery of anti-angiogenic antibodies in a liquid or solid 
polymeric vehicle such as hyaluronic acid or PLGA 
WO2010009034 
Intraocular delivery of anti-angiogenic antibodies in a liquid or solid 
polymeric vehicle such as hyaluronic acid or PLGA 
US20100098772 Delivery of anti-angiogenic agents with polymeric hyaluronic acid 
US20100074957 Injectable intraocular drug delivery system by use of microspheres 
US20090258924 Intraocular delivery of siRNA with a polymeric component 
Table 3. List of Patents on Intraocular Drug Delivery Systems 
3.3 Periocular dug derlivery route in AMD 
Periocular delivery includes such avenues as subconjunctival, retrobulbar, peribulbar, sub-
Tenon’s and intrascleral delivery. This route requires drugs to pass through several layers of 
ocular tissue (episclera, sclera, choroid, Bruch’s membrane, and RPE) to reach the retina or 
vitreous humor. Current knowledge shows that the combined effects of several static 
anatomic barriers and dynamic clearance mechanisms generally make periocular drug 
delivery one of the least effective ways of attaining high peak therapeutic intraocular drug 
concentrations in the retina or vitreous. These barriers are categorized into three major 
groups: static, dynamic and metabolic. Static barriers include the tissues that must be 
penetrated (e.g., sclera, Bruch’s membrane-choroid and RPE). Dynamic barriers include 
blood flow, lymphatic drainage, transport proteins of the RPE, drug efflux pumps, organic 
ion transporters and bulk fluid flow from intraocular drainage systems. Metabolic barriers 
include enzyme systems such as cytochrome P450 and lysosomal enzymes, which have the 
ability to degrade or detoxify drugs. In addition to the static, dynamic and metabolic 
barriers, other factors must be considered in periocular delivery such the individual 
pharmacokinetic properties of the drug (molecular dimensions, molecular weight, atomic 
charge and chemical components of the drug). Taken together these factors result in low 
intraocular bioavailability of drug delivered by the various periocular drug techniques, 
compared with that of intravitreal injection. 
Overall, when the safety and efficacy of this drug delivery route is compared with that of 
the others for the treatment of disease in the inner coat of the posterior segment, periocular 
injection is one of the best for safety, and it is in the middle to low end for efficacy, after 
intrinsic drug properties are factored in, such as potency and exposure–response 
relationships. With a few modifications, this route has the greatest potential to surpass 
intravitreal injection as the preferred treatment option for disease of the inner coat of the 
eye, since it deposits drug locally immediately adjacent to the targeted tissue without being 
overly invasive. 
A major adjuvant used to overcome the short to medium duration of action of periocular 
drug solutions is the development of several sustained drug release systems, whether 
through formulation modifications or through various sustained release drug delivery 
devices. Many of these options include liposomes, microspheres, and microcapsules with 
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diameters of 1–1000 μm, as well as nanospheres and nanocapsules with diameters of less 
than 1 μm, and biodegradable fibrin sealants (Bourges, Gautier, Delie, et al. 2003; Bu, 
Gukasyan, Goulet, et al. 2007; Guidetti, Azema, Malet-Martino, et al. 2008; Kearns & 
Williams, 2009). Polymeric microspheres have been used to target the RPE. Moritera et al. 
studied the use of surface-modified polymeric microspheres to localize drugs to the RPE 
(Moritera, Ogura, Yoshimura, et al. 1994). Phagocytosis by RPE was tracked by 
incorporating fluorescent dye into PLA microspheres with the rate of phagocytosis 
enhanced with gelatin-precoating as compared with bare microspheres. Intracellular dye 
release occurred following phagocytosis and could be controlled by varying the polymer 
formulation of the microspheres. Tuovinen et al. studied targeting drugs to the RPE using 
microparticles (11 μm in diameter) produced with starch acetate, which degrades more 
slowly than native starch (Tuovinen, Ruhanen, Kinnarinen, et al. 2004). These microparticles 
could be phagocytosed and degraded within the RPE. 
Nanospheres have also been used to target the RPE for sustained drug delivery. Sakurai et 
al. studied the intraocular kinetics of nanospheres and found that polystyrene nanospheres 
containing fluorescein (2 μm in diameter) were detectable in the retina, vitreous and 
trabecular meshwork more than 1 month following an intravitreal injection in vivo in 
rabbits (Sakurai, Ozeki, Kunou, et al. 2001). Anionic nanoparticles traversed the collagen 
fibrils of the vitreous more readily than the cationic nanoparticles, showing potential as 
drug delivery vehicles for the subretinal space and the RPE. Muller cells take up the 
nanoparticles, possibly playing a key role in retinal penetration. Micro- and nanoparticles 
have potential in the field of gene therapy by functioning as nonviral vectors to enable 
cellular penetration, guard against degradation and maintain sustained delivery. Bejjani et 
al. explored the use of PLA and PLGA nanoparticles as vectors for gene transfer to a bovine 
and a human ARPE-19 cell line (Bejjani, BenEzra, Cohen, et al. 2005), concluding that PLGA 
could successfully sequester and internalize plasmids, resulting in gene expression in RPE 
detectable 48 h postinjection and maintained for 8 days. Another therapeutic approach is the 
inhibition of gene expression using antisense oligonucleotides, aptamers and siRNA (Fattal 
& Bochot, 2006; Fattal & Bochot, 2008; Tanito, Li, Elliott, et al. 2007). Aukunuru et al. showed 
that nanoparticles formulated using a PLGA (50:50) copolymer could deliver VEGF 
antisense oligonucleotide to the human ARPE-19 cell line, and inhibit VEGF secretion and 
mRNA expression (Aukunuru, Ayalasomayajula & Kompella, 2003). In a study performed 
by Carrasquillo et al. (Carrasquillo, Ricker, Rigas, et al. 2003) and summarized by Moshfeghi 
and Peyman (Moshfeghi & Peyman, 2005), the anti-VEGF RNA aptamer (EYE001, 
Macugen®, OSI Pharmaceuticals, NY, USA) was incorporated into PLGA microspheres to 
develop a sustainedrelease inhibition of VEGF for the treatment of neovascular AMD. 
Transport and drug efficacy studies of micro- and nanoparticles administered via periocular 
injection have been also published (Amrite, Edelhauser, Singh, et al. 2008; Amrite & 
Kompella, 2005; Ayalasomayajula & Kompella, 2003; Ayalasomayajula & Kompella, 2004; 
Ayalasomayajula & Kompella, 2005; Chiang, Tung & Lu, 2001; Saishin, Silva, Saishin, et al. 
2003). In conclusion nano- and microparticles have shown great potential for expanding the 
arsenal of drug-delivery systems available for treating posterior segment disease. They 
provide sustained delivery and reduce complications that result from treatments requiring 
multiple injections. Transscleral delivery of anti-VEGF drugs loaded in PLA or PLGA nano- 
and microparticles is gaining much attention as a feasible and effective method of 
administration for the treatment of posterior segment disease. 
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3.4 Hybrid drug delivery in AMD 
Minimally invasive hollow and solid microneedles (<1 mm diameter) have been developed 
to deliver drugs into the cornea, sclera, or suprachoroidal space to avoid some of the 
shortcomings in safety and bioavailability with intravitreal or periocular injection. Solid, 
drug-coated microneedles are used for intracorneal and intrascleral drug delivery, 
improved bioavailability, and duration of action. Hollow microneedles are used for 
intrascleral and suprachoroidal delivery of a sustained-release drug depot in a tissue layer, 
with clearance mechanisms that are minimal or less than those in the subconjunctival or 
sub-Tenon’s space. Microneedles allow for better retinochoroidal targeting than periocular 
drug delivery, because it is closer to the target tissue (Jiang, Gill, Ghate, et al. 2007; Jiang, 
Moore, Edelhauser, et al. 2009). A hollow microcatheter cannulation drug delivery technique 
has also been developed for suprachoroidal drug delivery. 
It is more directly invasive than the hollow microneedle approach, but microcatheter 
delivery may be promising for sustained drug delivery if it can be shown that continuous 
infusion of drugs into the suprachoroidal space can be tolerated better than a one-time 
injection with a microneedle. Overall, despite being relatively new and having few 
longterm data, the hybrid delivery route is arguably the second best for safety (tied with 
periocular and just behind topical) and second best for efficacy (the best being 
intraocular). This ranking has not been definitively proven in clinical trials. Another 
drawback that has not yet been calculated is the greater expense associated with this 
technology. 
3.5 Topical drug delivery in AMD 
Topical application to the anterior eye has been proven successful in the treatment of 
diseases owing to easy access to the target site. However, the adoption of mechanisms in 
ensuring topical drug penetration to the posterior eye presents numerous challenges. It is 
difficult to predict which drugs can achieve adequate therapeutic levels in the inner coat of 
the posterior segment after topical drug delivery and whether penetration can be enhanced 
by structural modifications or a particular formulation (Ghate & Edelhauser, 2006). Thus, 
experimental testing in animal models is critical. As this drug delivery route has two major 
shortcomings, extremely poor bioavailability to the inner coat of the posterior segment and a 
short duration of action, the main adjuvants are penetration enhancers and sustained-release 
drug delivery systems. Paracellular penetration by topical drugs can be improved by several 
mechanisms including: opening TJs by using preservatives in topical medications or by 
iatrogenic epithelial scraping; increasing drug lipophilicity through the use of prodrugs or 
other analogues, such as surfactants, and binding the drugs to dendrimers that use carrier-
mediated influx transporters. 
Recent research has focused on small-molecule penetration into the vitreous, with evidence 
that molecules with lower molecular weight have increased permeability into the posterior 
chamber. Molecules with higher molecular weights and superior water solubility (highly 
charged) may have longer half-lives than those with lower molecular weights. Thus, lower 
molecular-weight compounds have increased access to the posterior eye and may minimize 
the risk of toxicity compared with higher molecular-weight compounds, which degrade at 
www.intechopen.com
 
Age Related Macular Degeneration – The Recent Advances in Basic Research and Clinical Care 
 
112 
slower rates. Therefore, each drug must be individually assessed and its uptake, efficiency 
and safety must be determined. As the list of drugs that achieve therapeutic levels in the 
retina and choroid after topical administration increases, it may be possible to identify 
structural characteristics that promote ocular penetration and to specifically design drugs 
and/or prodrugs accordingly. Another new technique is represented by Iontophoresis that 
is an old technology recently modified into a new innovative drug delivery platform. Recent 
clinical trials have demonstrated that iontophoresis is sufficiently safe and capable of 
delivering steroids to ocular tissue to some oculare disease (uveitis). It is performed by 
applying a small electrical current that has the same charge as the drug to create repulsive 
electromotive forces (Hayden, Jockovich, Murray, et al. 2006; Hughes, Olejnik, Chang-Lin, et 
al 2005; Myles, Neumann & Hill, 2005).  
3.6 Systemic drug delivery routes 
There have been advances in the use of systemic medications for the treatment of 
ophthalmic diseases, despite several limitations related to systemic penetration of many 
drugs, particularly large or hydrophilic ones, into the posterior segment of the eye. Further 
movement from the choroid into internal ocular structures such as the retina and vitreous 
humor, especially of large and/or hydrophilic drugs, is restricted by the RPE (oBRB) and TJs 
of the retinal vasculature (iBRB). Small lipophilic drugs, however, can penetrate the oBRB 
and iBRB, achieving appreciable concentrations in the retina and vitreous humor after 
systemic administration. The systemic application of drugs not only increases the quantity 
of a drug necessary to achieve therapeutic concentrations, but it also increases the risk of 
adverse effects due to the accumulation of a drug in other tissues throughout the body. 
Another limitation of systemic application includes potential reduced time of therapeutic 
effects and potency due to the dilution and degradation of the drug before reaching the 
target site. Despite these limitations, there have been advances in the use of systemic 
medications for the treatment of ophthalmic diseases.  
To the wide sense, PDT with verteporfin is one of drug targeting systems. After intravenous 
administration, verteporfin, a relatively hydrophobic compound, is incorporated into 
lipoproteins. According to preferential accumulation of lipoproteins in and around 
choroidal neovascular membrane, verteporfin tends to be targeted into CNV. The 
photosensitizer targeted injures and closes new vessels in combination of laser irradiation to 
pathological lesion. However, most systemic drugs are now formulated with excipients that 
help overcome their tendency toward a brief duration of action and poor to medium 
bioavailability to the inner coat of the posterior segment.  
One novel scheme to enhance the bioavailability of systemic drugs to the retina are 
penetration enhancers that help reversibly open up the BRB or improve transcellular 
penetration. Because TJ proteins are not very antigenic, it is difficult to develop antibodies 
against their extracellular domain, a fact that has severely hampered the development of TJ 
modulators. For example a novel approach to treat retinal disease by systemic drug delivery 
reviewed the role of the complement pathway in the pathogenesis of ARMD. Dysregulation 
of the alternate complement pathway, especially in the C3 amplification loop, may be a 
reasonable target for treating AMD and inflammatory retinal diseases by administering the 
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intravenous fusion protein complement receptor 2 and factor H (CR2-fH), to recognize and 
inhibit complement- activation products (Holers, 2008; Rohrer, Long, Coughlin, et al. 2009; 
Thurman & Holers, 2006). Complement receptor 2 recognizes C3d, a tissue-bound activation 
product of complementmediated inflammation (e.g., drusen), whereas the fH component of 
the fusion molecule is the most potent inhibitor of the alternative complement pathway. 
Some experimental studies have shown how the oxidative stress sensitizes RPE cells to 
complement-mediated attack by decreasing regulatory cell surface membrane-bound 
complement inhibitors to the alternative pathway.  
That oxidative stress also alters RPE cells in such a way that soluble fH in the serum is less 
functionally protective (Thurman, Renner, Kunchithapautham, et al. 2009). Complement-
mediated attack of the RPE then results in sublytic activation of the membrane attack 
complex resulting in vascular endothelial growth factor VEGF release and breakdown of the 
oBRB (Thurman, Renner, Kunchithapautham, et al. 2009). In humans, this cascade of events 
can result in either dry geographic atrophy or wet AMD. Systemic CR2-fH therapy protects 
the retina using experimental mouse models of retinal degeneration and choroidal 
neovascularization. 
4. Conclusion 
Basic research and open clinical trials have provided breakthrough therapies for treatment 
of diseases of the posterior segment of the eye, such as the use of anti-VEGF agents for the 
treatment of AMD. More effective drugs and drug-delivery systems are needed to decrease 
the frequency of drug administration. Multiple drugs and drug delivery systems may be 
required to safely and successfully treat some conditions. However, effective treatment of 
posterior segment ophthalmic diseases represents a formidable challenge for scientists and 
clinicians in the ophthalmic pharmaceutical field. The challenges include the anatomic and 
physiologic barriers that can impede pharmacologically active levels of drug from reaching 
the targeted tissues inside the eye, immune reactions and clearance mechanisms to certain 
drugs and drug delivery materials, and the often irreversible nature of vision loss. A better 
understanding must be developed of the nature and effect of dynamic physiologic processes 
of the eye, such as clearance mechanisms and metabolism of drugs in specific tissue layers. 
Each static anatomic barrier encountered for each specific drug delivery technique must be 
better studied. Drug–protein or drug–pigment binding must be better characterized with 
needing of more research in formulation modifications that alter physicochemical properties 
of both new and old drugs, facilitating delivery through known paracellular and 
transcellular pathways. Ophthalmic drug delivery via nanotechnology-based products, 
development of ophthalmic gene delivery must be further explored, given the extensive 
potential of this technology. However a new “era” is coming, in which application of 
technological advances in vision science is progressing at a rapid rate. Advances in 
nanotechnology, gene therapy, and biomaterials, for example, hold promise for providing 
new solutions to the challenge of ocular drug delivery. 
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